Page 8 - Pascal Deschatelets News Today

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its price objective upped by stock analysts at Bank of America from $112.00 to $114.00 in a research note issued to investors on Friday, The Fly reports. Bank of America‘s price target indicates a potential upside of 35.12% from the stock’s current price. Several other brokerages have also […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its price objective hoisted by Wells Fargo & Company from $55.00 to $76.00 in a research note issued to investors on Friday, The Fly reports. Wells Fargo & Company‘s target price would suggest a potential downside of 9.92% from the company’s previous close. Several other equities analysts also […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating)’s share price traded down 6.1% during mid-day trading on Thursday . The stock traded as low as $78.14 and last traded at $79.55. 898,539 shares changed hands during trading, a decline of 47% from the average session volume of 1,702,431 shares. The stock had previously closed at $84.68. […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) shares traded down 6.1% on Thursday . The company traded as low as $78.14 and last traded at $79.55. 898,539 shares were traded during trading, a decline of 47% from the average session volume of 1,702,431 shares. The stock had previously closed at $84.68. Analyst Upgrades and Downgrades […]

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $88.51 and last traded at $88.27, with a volume of 1040253 shares traded. The stock had previously closed at $86.25. Analyst Ratings Changes A number of research analysts have […]

Should You Buy or Sell Apellis Pharmaceuticals Stock? Get The Latest APLS Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.

EFG Asset Management North America Corp. lessened its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) by 7.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,377 shares of the company’s stock after selling 1,955 shares during the quarter. EFG […]

HC Wainwright restated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) in a report released on Thursday, Benzinga reports. They currently have a $87.00 price objective on the stock. Several other brokerages also recently commented on APLS. Robert W. Baird boosted their target price on Apellis Pharmaceuticals from $90.00 to $105.00 […]

Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) had its price target hoisted by The Goldman Sachs Group from $124.00 to $141.00 in a report released on Friday, Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages also recently commented on APLS. Wedbush lifted their target price on Apellis Pharmaceuticals from […]

Should You Buy or Sell Apellis Pharmaceuticals Stock? Get The Latest APLS Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.